Ask AI
Individualized obesity care TM

CE / CME

Enhancing Outcomes in Obesity Care With Incretin-Based Therapy and Individualized Treatment Plans

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

ABIM MOC: maximum of 0.50 Medical Knowledge MOC point

Physicians: maximum of 0.50 AMA PRA Category 1 Credit

Nurse Practitioners/Nurses: 0.50 Nursing contact hour

Released: July 15, 2026

Expiration: July 14, 2027

Activity

Progress
1 2 3
Course Completed

References

  1. Sumithran P, Prendergast LA, Delbridge E. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011;365:1597-604.
  2. Angelidi AM, Belanger MJ, Kokkinos A, et al. Novel noninvasive approaches to the treatment of obesity: from pharmacotherapy to gene therapy. Endocr Rev. 2022;43:507-557.
  3. Tak YJ, Lee SY. Long-term efficacy and safety of anti-obesity treatment: where do we stand? Curr Obes Rep. 2021;10:14-30.
  4. Alcaino C, Reimann F, Gribble FM. Incretin hormones and obesity. J Physiol. 2025;603:7645-7659.
  5. Radparvar I, Agrawal DK. A critical analysis of the clinical use of incretin-based therapies: efficacy and adverse events. Arch Clin Med Case Rep. 2025;9:242-253.
  6. Atlantis E, Wu R, Dixon J. Incretin-based therapies for obesity and disordered eating: optimising care in general practice. Fam Med Community Health. 2026;14(Suppl 2):e003622.
  7. Liraglutide [prescribing information]. Plainsboro, NJ: Novo Nordisk, Inc.; 2026.
  8. Semaglutide [prescribing information]. Plainsboro, NJ: Novo Nordisk, Inc.; 2026.
  9. Orforglipron [prescribing information]. Indianapolis, IN: Lilly USA, LLC; 2026.
  10. Tirzepatide [prescribing information]. Indianapolis, IN: Lilly USA, LLC; 2026.
  11. PR Newswire. Epitomee medical announces FDA clearance of its capsule, weight management device. prnewswire.com/news-releases/epitomee-medical-announces-fda-clearance-of-its-capsule-weight-management-device-302249169.html. Accessed June 29, 2026.
  12. Melson E, Ashraf U, Papamargaritis D, et al. What is the pipeline for future medications for obesity? Int J Obes (Lond). 2025;49:433-451.
  13. Nadolsky K, Garvey WT, Agarwal M, et al. American Association of Clinical Endocrinology consensus statement: algorithm for the evaluation and treatment of adults with obesity/adiposity-based chronic disease - 2025 update. Endocr Pract. 2025;31:1351-1394.
  14. American Diabetes Association Professional Practice Committee for Diabetes*. 8. Obesity and weight management for the prevention and treatment of diabetes: standards of care in diabetes-2026. Diabetes Care. 2026;49(Supplement_1):S166-S182.
  15. Horn DB, Almandoz JP, Look M. What is clinically relevant weight loss for your patients and how can it be achieved? A narrative review. Postgrad Med. 2022;134:359-375.